X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Given Average Recommendation of “Hold” by Brokerages

Shares of X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) have earned a consensus rating of “Hold” from the five ratings firms that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have issued a buy recommendation on the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $34.50.

Several research firms have recently issued reports on XFOR. Zacks Research lowered X4 Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, November 26th. Stifel Nicolaus set a $10.00 price objective on shares of X4 Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, December 5th. Wall Street Zen cut shares of X4 Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Sunday, November 30th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of X4 Pharmaceuticals in a report on Monday, December 29th.

X4 Pharmaceuticals Stock Up 7.3%

NASDAQ:XFOR opened at $3.39 on Wednesday. The company has a quick ratio of 5.48, a current ratio of 5.65 and a debt-to-equity ratio of 1.23. X4 Pharmaceuticals has a 12-month low of $1.35 and a 12-month high of $13.80. The stock’s fifty day simple moving average is $3.74 and its 200-day simple moving average is $3.56. The firm has a market capitalization of $296.42 million, a P/E ratio of -0.33 and a beta of 0.46.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Bank of America Corp DE increased its stake in X4 Pharmaceuticals by 20.3% during the 4th quarter. Bank of America Corp DE now owns 133,502 shares of the company’s stock worth $98,000 after purchasing an additional 22,485 shares in the last quarter. Rhumbline Advisers lifted its position in X4 Pharmaceuticals by 5.4% in the 1st quarter. Rhumbline Advisers now owns 188,415 shares of the company’s stock valued at $44,000 after acquiring an additional 9,690 shares in the last quarter. Jane Street Group LLC lifted its position in X4 Pharmaceuticals by 112.5% in the 2nd quarter. Jane Street Group LLC now owns 97,344 shares of the company’s stock valued at $185,000 after acquiring an additional 51,544 shares in the last quarter. Vanguard Group Inc. boosted its stake in X4 Pharmaceuticals by 77.0% in the 3rd quarter. Vanguard Group Inc. now owns 410,485 shares of the company’s stock worth $1,404,000 after purchasing an additional 178,593 shares during the period. Finally, Palumbo Wealth Management LLC bought a new position in X4 Pharmaceuticals during the 3rd quarter worth about $326,000. 72.03% of the stock is currently owned by institutional investors.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the C-X-C chemokine receptor type 4 (CXCR4) for the treatment of rare immunological diseases and oncology indications. The company’s lead asset, mavorixafor, is an orally administered, selective small-molecule CXCR4 antagonist designed to mobilize white blood cells and enhance immune function, with a primary focus on WHIM syndrome, a rare congenital immunodeficiency.

Beyond its WHIM syndrome program, X4 is advancing mavorixafor in clinical trials for additional hematologic and solid tumor settings—such as Waldenström’s macroglobulinemia and chronic lymphocytic leukemia—where modulation of the CXCR4 pathway may improve patient outcomes.